ORLANDO, FL USA (UroToday.com) - PSADT helps to stratify risk of death from recurrent CaP after surgery; <3 months results in 100% mortality. D’Amico showed that this is also important for post-RT patients. ADT improves freedom from disease recurrence in men with a fast PSADT, but less so for a slow (>12 months) PSADT. He then discussed intermittent androgen deprivation therapy. The goals are to prolong time to castration-resistance and lessen toxicity. The SWOG data on this is pending. Other approaches are to use bicalutamide monotherapy, but two underpowered studies did not show benefit. An anti-androgen plus 5-ARI study in older patients is ongoing. Regarding new therapies, the amplified androgen receptor is targeted by abiraterone. However, are they useful in earlier, non-amplified AR disease? Neo-adjuvant pre-surgery use of abiraterone is being studied, but some of the first patients had an excellent response, including P0. Using combinations of androgen-targeted drugs holds great promise going forward, Dr. Small concluded.
Presented by Eric J. Small, MD at the 2011 Genitourinary Cancers Symposium, General Session II: Prostate Cancer Therapy for Recurrent Disease - February 17-19, 2011 - Orlando World Center Marriott, Orlando, Florida USA
